Exosomes vs Stem Cells: Not the Same Thing

Exosome treatments have spread rapidly through clinics, often positioned as the newer, better option. They are not stem cells, and the difference is not a technicality.

What an exosome is

Cells release tiny membrane-bound packages containing proteins, lipids and genetic material such as microRNA. These are extracellular vesicles, commonly called exosomes. They are how cells send signals to each other.

The key distinction: an exosome is a package released by a cell, not a cell. It is not alive. It cannot divide, cannot respond to its environment, and cannot become tissue.

	Stem cells (MSCs)	Exosomes
Living	Yes	No
Can divide	Yes	No
Can become tissue	In a dish, yes	No
Mechanism	Mostly signalling	Signalling only
Storage	Demanding — cold chain, viability decays	Simpler, more stable
Rejection risk	Low but present	Minimal
Typical price	$5,000–$25,000	$2,000–$10,000
FDA approved	No	No

The logic behind them

It is not unreasonable. If MSCs work mainly by releasing signalling molecules rather than by becoming new tissue — which is what current evidence suggests — then delivering the signals directly, without the cells, is a coherent idea. Exosomes are also easier to store, ship and standardise.

That is a legitimate research direction. It is not the same as an established treatment.

The regulatory position

No exosome product has FDA approval for any use. The FDA has issued specific public warnings about unapproved exosome products, and has taken enforcement action against distributors. Serious adverse events, including bacterial infections, have been linked to unapproved exosome products administered at clinics.

Exosome products are regulated as biological drugs. Clinics selling them are selling an unapproved drug.

The evidence

Thinner than for MSCs, and MSC evidence is already weak for most marketed uses.

Preclinical work in cells and animals is genuinely interesting across several conditions. Human randomised controlled evidence for the indications sold in clinics — joints, skin, hair, neurological conditions — is largely absent.

The quality control problem

This is the sharpest concern.

There is no standardised, FDA-supervised manufacturing for these products, and no agreed potency assay. Independent analyses of commercially sold exosome preparations have found wide variation in particle counts and content, with some products containing far less than claimed.

With a cell product you can at least ask for a viability count. With exosomes, most clinics cannot tell you what is in the vial, because the supplier cannot either. You are buying an unlabelled preparation from an unregulated supply chain.

Where it is heading

Exosome and extracellular vesicle research is one of the more promising areas in regenerative medicine, and it is plausible that approved products will eventually exist. Being promising in research is not the same as being ready to sell, and the current commercial market is running well ahead of the science.

Sources

1. US Food and Drug Administration — public safety notification on exosome products; warning letters to distributors.
2. Reports of adverse events associated with unapproved exosome products administered in clinics.
3. International Society for Extracellular Vesicles — position statements on therapeutic applications and characterisation standards.

---